AlphaValue Corporate Services Fundamental Analysis FR
Back to
AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Ikonisys

CR
Bloomberg   ALIKO FP
Med Tech  /  France  Web Site   |   Investors Relation
A ‘fully-automated’ oncology diagnostic play
Graphs     Help
Perf. 1W: 0.36%- Perf. 1M: -1.06%- Perf. 3M: -7.62%- Perf Ytd: n/a
10 day relative perf. to stoxx600: 2.00%- 20 day relative perf. to stoxx600: 0.17%